Skip to main content
1994
2000
2001
- AtriCure Bipolar Ablation System cleared
- First-generation Isolator Clamp (LHP1) cleared
2002
- AtriCure Bipolar Ablation System released to market including second-generation Bipolar Ablation Clamp (LHP2) and second-generation Ablation Sensing Unit (ASU2)
- AtriCure received its first CE Mark approval that included the Bipolar Ablation System
- Washington University published the seminal paper on AtriCure’s Bipolar Radiofrequency Technology
2003
- Foundational patent 6,517,536 and 6,546,935 issued for “Device and Methods for Transmural Ablation”
- First commercial sale that included the Bipolar Ablation Clamp
2004
- Lumitip™ Dissector released to market
- First international sale that was sold to Belgium
2005
- Isolator® Transpolar™ Pen (MAX1) released to market
- AtriCure listed on NASDAQ
- AtriCure opened its European office in the Netherlands
2006
- Isolator® Transpolar™ Long Pen (MAX5) released to market
- Isolator® Transpolar™ System released to market including the Isolator Clamps (OLL1, EMR1 and EML1)
2007
- AtriCure Synergy Bipolar Ablation System released to market including the Isolator Synergy Clamps (OLL2, OSL2, EMR2 and EML2) along with AtriCure Switch Matrix (ABS3)
- First AtriClip device implanted
- AtriCure entered the Cryosurgical market
2008
- Isolator Coolrail® Linear Pen released to market
- ABLATE Clinical Trial enrollment initiated
- EXCLUDE Clinical Trial enrollment initiated
- Continued to grow international presence by selling products in over 25 countries
2009
- CRYO1 Cryoablation Probe released to market
- ORLab® System released to market
- DEEP (Hybrid) Clinical Trial enrollment initiated
2010
- AtriClip Left Atrial Appendage (LAA) Exclusion System released to market
- AtriClip ACH1 device released to market
- CRYO2 cryoICE® Cryoablation Probe released to market
- Multifunctional Linear Pen released to market
2011
- AtriCure Cryo Module System released to market
- Isolator Synergy System approved for treatment of persistent or long-standing persistent atrial fibrillation
- Isolator Synergy Access Clamp released to market
2012
- AtriClip PRO® device released to market
- DEEP (Staged) Clinical Trial enrollment initiated
- Maze IV Training Program initiated
- AtriCure hosted 25th Anniversary of the Cox Maze Procedure
- Over 100,000 ablations performed
2013
- Established Professional Education Program
- AtriCure expanded the Maze IV Training Program to Europe
- AtriCure acquired Endoscopic Technologies, Inc. (Estech)
2014
- AtriClip FLEX device (ACH2) released to market
- CRYO3 cryoICE Cryoablation Probe and AtriCure Cryo Module Version 6 (ACM V6) released to market
- ABLATE-PAS Clinical Trial completes enrollment
- DEEP (Pivotal) Clinical Trial enrollment initiated
- Completed requirement to train U.S. surgeons on Synergy Clamp per FDA mandate
- Minneapolis office opened
- Over 150,000 ablations performed
2015
- cryoICE® probe made available for Cryo Nerve Block applications
- CEASE-AF Clinical Trial enrollment initiated
- Dr. James L. Cox American Association for Thoracic Surgery (AATS) Fellowship Training Program established
- Introduced Advanced Ablation weekend training courses
- AtriCure acquired nContact Surgical, LLC.
- Cincinnati headquarters earned “Top Workplaces 2015” designation
- New headquarters opened in Mason, Ohio, near Cincinnati
- 200,000 ablations performed and 50,000 AtriClip devices sold
- Continued to grow international presence by selling products in over 50 countries
2016
- AtriClip PRO2® device released to market
- cryoFORM® Probe released to market
- ATLAS Clinical Trial enrollment initiated
- FROST Clinical Trial enrollment initiated
- Cincinnati headquarters earned “Top Workplaces 2016” designation
- The Society of Thoracic Surgeons (STS) 2017 Clinical Practice Guidelines recommend Afib ablation treatment
- Gained approval for the AtriClip® products and cryoICE® platform in Japan
2017
- AtriClip PRO•V® device released to market
- Introduced Nurse Continuing Education Unit (CEU) Course for Ablation and Left Atrial Appendage Management
- Heart Rhythm Society (HRS) provide Class I recommendation
- Over 250,000 ablations performed and surpassed 100,000 AtriClip devices sold worldwide
2018
- AtriClip® FLEX•V® released to market
- CONVERGE IDE Clinical Trial completes enrollment
- AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
- Cincinnati headquarters earned “Top Workplaces 2018” designation
2019
- cryoICE cryoSPHERE™ Probe released to market
- Received expanded labeling claims for AtriClip devices
- ICE-AFIB Clinical Trial enrollment initiated
- First national Fellows Concomitant Ablation Training Course led by Northwestern Faculty Drs. McCarthy and Cox
- AtriCure acquired SentreHEART, Inc.
- Cincinnati headquarters earned “Top Workplaces 2019” designation
- Facility expansions at headquarters and European location
- The Society of Thoracic Surgeons (STS) endorses AtriCure’s Advanced Ablation Courses in the United States
- Over 2,500 healthcare professionals trained, more than 350,000 ablations performed, and surpassed 200,000 AtriClip devices sold worldwide
2020
- MO100000 marked the 100,000th production build
- aMAZE Clinical Trial completes enrollment
- Cincinnati headquarters earned “Top Workplaces 2020” designation along with its Minnetonka office being named a “2020 National Standard Top Workplace” by the Minneapolis Star Tribune
2021
- Received expanded labeling for Cryo Nerve Block Therapy
- EPi-Sense® Guided Coagulation System approved for treatment of long-standing persistent atrial fibrillation
- Cincinnati headquarters earned “Top Workplaces 2021” designation
- AtriCure surpasses one million devices produced
2022
- Isolator® Synergy™ EnCompass® Clamp released to market
- HEAL-IST™ Clinical Trial enrollment initiated
- Cincinnati headquarters earned “Top Workplaces 2022” designation
- Minnetonka office named a “2022 National Standard Top Workplace” by the Minneapolis Star Tribune
- Amsterdam office received the “Great Place to Work” certification
- AtriCure wins 2022 National Association of Corporate Directors (NACD) Diversity, Equity, & Inclusion Award
2023
- LeAAPS Clinical Trial enrollment initiated
- EPi-Sense ST™ Device released to market